Literature DB >> 27236057

Pharmacologic Approaches to the Treatment of Obstructive Sleep Apnea.

David P White1.   

Abstract

The concept of pharmacologic therapy for obstructive sleep apnea (OSA) treatment has always been considered but no agent has had a large enough effect size to drive substantial adoption. A new construct of the pathophysiology of OSA is that there are 4 primary physiologic traits that dictate who develops OSA. These traits vary substantially between patients, meaning OSA may develop for quite different reasons. This encourages new thinking regarding pharmacologic therapy and continued attempts to find the ideal or acceptable drug.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apnea; Arousal threshold; Loop gain; Pharmacology; Phenotypes; Sleep

Mesh：

Year:  2016        PMID： 27236057     DOI： 10.1016/j.jsmc.2016.01.007

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN： 1556-407X


  9 in total

Review 1.  Speckle tracking echocardiography in heart failure development and progression in patients with apneas.

Authors:  Giulia Elena Mandoli; Chiara Borrelli; Matteo Cameli; Sergio Mondillo; Lorenzo Ghiadoni; Claudia Taddei; Claudio Passino; Michele Emdin; Alberto Giannoni
Journal:  Heart Fail Rev       Date:  2021-12-01       Impact factor: 4.654

2.  Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea.

Authors:  Corrado Pelaia; Giuseppe Armentaro; Mara Volpentesta; Luana Mancuso; Sofia Miceli; Benedetto Caroleo; Maria Perticone; Raffaele Maio; Franco Arturi; Egidio Imbalzano; Francesco Andreozzi; Francesco Perticone; Giorgio Sesti; Angela Sciacqua
Journal:  Front Cardiovasc Med       Date:  2022-04-05

3.  The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease.

Authors:  Hyeyun Kim; Hyun Jeong Han
Journal:  Dement Neurocogn Disord       Date:  2016-12-31

Review 4.  The Role of Animal Models in Developing Pharmacotherapy for Obstructive Sleep Apnea.

Authors:  Lenise Jihe Kim; Carla Freire; Thomaz Fleury Curado; Jonathan C Jun; Vsevolod Y Polotsky
Journal:  J Clin Med       Date:  2019-11-22       Impact factor: 4.241

5.  Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing.

Authors:  Thomaz Fleury Curado; Huy Pho; Carla Freire; Mateus R Amorim; Jordi Bonaventura; Lenise J Kim; Rachel Lee; Meaghan E Cabassa; Stone R Streeter; Luiz G Branco; Luiz U Sennes; Kenneth Fishbein; Richard G Spencer; Alan R Schwartz; Michael J Brennick; Michael Michaelides; David D Fuller; Vsevolod Y Polotsky
Journal:  Am J Respir Crit Care Med       Date:  2021-01-01       Impact factor: 21.405

Review 6.  Obstructive sleep apnea: current perspectives.

Authors:  Amal M Osman; Sophie G Carter; Jayne C Carberry; Danny J Eckert
Journal:  Nat Sci Sleep       Date:  2018-01-23

7.  Silencing of Hypoglossal Motoneurons Leads to Sleep Disordered Breathing in Lean Mice.

Authors:  Thomaz A Fleury Curado; Huy Pho; Olga Dergacheva; Slava Berger; Rachel Lee; Carla Freire; Aya Asherov; Luis U Sennes; David Mendelowitz; Alan R Schwartz; Vsevolod Y Polotsky
Journal:  Front Neurol       Date:  2018-11-14       Impact factor: 4.003

8.  Differential activating effects of thyrotropin-releasing hormone and its analog taltirelin on motor output to the tongue musculature in vivo.

Authors:  Wen-Ying Liu; Hattie Liu; Jasmin Aggarwal; Zhi-Li Huang; Richard L Horner
Journal:  Sleep       Date:  2020-09-14       Impact factor: 5.849

9.  Modulation of TASK-1/3 channels at the hypoglossal motoneuron pool and effects on tongue motor output and responses to excitatory inputs in vivo: implications for strategies for obstructive sleep apnea pharmacotherapy.

Authors:  Patrick Gurges; Hattie Liu; Richard L Horner
Journal:  Sleep       Date:  2021-01-21       Impact factor: 5.849
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.